No Data
Haisco Pharmaceutical's Unit to Carry Out Trials on Lung Disease Drug
Haisco Pharmaceutical Group (002653.SZ): Received the notice of approval for the clinical trial of innovative drug HSK44459 tablets.
On August 7th, Gelonhui reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Sichuan Haisco Pharmaceutical Co., Ltd., recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The drug name is HSK44459 tablet, and the indication is for interstitial lung disease. HSK44459 is a new, independently developed, and proprietary phosphodiesterase 4B (PDE4B) inhibitor of cyclic nucleotides that can achieve anti-inflammatory and anti-fibrotic effects by inhibiting the effusion of inflammatory factors (mainly) and the proliferation and activation of fibroblasts. Compared to traditional drugs.
Is Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) Stock On A Downtrend As A Result Of Its Poor Financials?
Haisco Pharmaceutical Group (002653.SZ) has gained approval to conduct clinical trials on the innovative drug HSK39004 inhalation suspension.
On July 25th, Geelong News reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. After review, the HSK39004 inhalation suspension, which was accepted in May 2024, meets the requirements for drug registration, and the clinical trial of the drug is approved. HSK39004 is a new targeted small molecule inhibitor with independent intellectual property rights independently developed by the company. It is clinically intended for the treatment of chronic obstructive pulmonary Disease. The preclinical research results show that HSK39004 has a good therapeutic effect on COPD in vitro.
Haisco Pharmaceutical Group's (SZSE:002653) Investors Will Be Pleased With Their Notable 82% Return Over the Last Five Years
Haisco Pharmaceutical Group (002653.SZ) has launched three phase III clinical trials for its hydroquinone project in the USA, two of which have been completed.
Haisco Pharmaceutical Group (002653.SZ) stated on the investor interaction platform on July 16 that the company has launched three Phase III clinical studies for its Hydroquinone project in the United States, two of which have been completed, and the other is progressing normally. The company is actively advancing related work and hoping to submit an NDA application to the FDA in the first half of 2025.
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling YouNo Data
